Promise Of MolDx Program For Molecular Tests Unfulfilled, Labs Say
This article was originally published in The Gray Sheet
Executive Summary
Benefits to test makers and users from the Medicare MolDx program have not been fully reaped, diagnostic reimbursement experts said at a recent Avalere summit.
You may also be interested in...
Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence
Diagnostic industry players support the regional Medicare contractor’s evidence-based reimbursement requirements for molecular diagnostics and are hoping CMS adopts the approach nationally.
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.